XNAS · Medical Devices
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$79.92-1.42%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
55/100
Positive
Score components
TickerWhale View
Dexcom scores 55 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Valuation its weakest.
What helps
- Quality & growth
- Sentiment Signal
What to watch
- Technical
- Valuation
- Risk
Quality & growth
30%96Strong
- Revenue growth 15.5%
- EPS growth 76.2%
Valuation
25%30Weak
- P/E 31.2
- EV/Sales 6.3
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
#341 by market cap in our coverage · ~11,100 employees · Listed 2005-04-14 · www.dexcom.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#77 / 139sector rank by TickerWhale Score
TickerWhale Score 55 vs sector average 54.6 (+0.4)
Revenue growth (industry)Top 33%
Gross margin (industry)Top 67%
Return on equity (industry)Top 6%
P/E (industry)Cheaper than 53%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
39/100Weak vs universe
Ranks 39th of 100 covered names on our technical composite — the composite itself scores 49/100 · 25% of the TickerWhale Score
Classic chart indicators
Neutral
2 buy · 2 sell · 4 neutral of 8 votes
TickerWhale rates DXCM's technical setup weak — 39th percentile of the covered universe. Classic chart indicators lean neutral — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
2 / 9constructive
- vs 200-day+6.6%
- vs 50-day-5.7%
Momentum
Mixed
- RSI (14)44 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength20· trending
- MACD (12,26,9)buy(histogram 0.050)
How the classic verdict is reached
Moving averages (9) agree on sell — 2 buy vs 7 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 1 sell · 4 neutral.
Result — 2 buy vs 2 sell of 8 votes = Neutral. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)31.2
- P/S (TTM)6.3
- P/B11.9
- EV/EBITDA—
- EV/Sales6.3
- PEG—
Profitability & returns
- Gross margin62.5%
- Net margin20.1%
- ROE35.8%
- Debt/Equity0.47
Growth
- Revenue growth (YoY)15.5%
- EPS growth (YoY)76.2%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $31.2B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DXCMCurrentDexcom | 55 | 49 | 31.2 | — | 11.9 | 6.3 | $79.92 | -1.42% | +15.5% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.